Background: Lung transplantation remains the best treatment option for a variety of end-stage lung diseases. Pressure on the limited donor pool has led to the use of extended criteria donors. One aspect of this has been the liberalization of the use of smoking donors (SmD).
Methods: This study is a retrospective review of lung transplants performed between April 1995 and August 2008 at a single institute. We examined the impact of donor smoking on short-term and long-term survival in relationship to recipient and donor demographics such as ischemic time, cytomegalovirus status, rates of rejection and infection, ventilation, and intensive care stay. Endpoints were survival, infection, and rejection.
Results: During this 13-year period, 454 lung transplants were performed. Smoking history was available on 424 (93.4%) of these (SmD, n = 184; NSmD, n = 240). Seventy-one patients died within 3 months of transplant leaving 353 alive at 3 months posttransplant. Fatalities within the first 3 months were significantly higher in the SmD group (21% vs 13%, odds ratio 1.9, hazard ratio 3.3, p = 0.04). No significant difference in rejection and infection rates between recipients of lungs from SmD and NSmD at 3 months and at 1 year posttransplantation (p = 0.51 and 0.09) was found. Although recipients of lungs from SmD had higher odds of ventilation for more than 10 hours, the odds were only increased by 20%, which was not statistically significant. Recipients from SmD had significantly longer stays in the intensive care (odds ratio 1.9, p = 0.002). There was little evidence for an effect of SmD on the development of bronchiolitis obliterans.
Conclusions: In this large cohort of patients, donor smoking history has an effect on early survival but no effect on long-term survival. The cause of this early mortality is independent of infection and rejection. However, these data suggest that overall outcomes from the use of donor lungs from smokers are acceptable, particularly in the current era with limited donor organs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2010.07.073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beyond Polymerization: In Situ Coupled Fluorination Enables More Stable Interfaces for Solid-State Lithium Batteries.
J Am Chem Soc
January 2025
Nanoyang Group, Tianjin Key Laboratory of Advanced Carbon and Electrochemical Energy Storage, School of Chemical Engineering and Technology, National Industry-Education Integration Platform of Energy Storage, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin University, Tianjin 300072, China.
In situ polymerization strategies hold great promise for enhancing the physical interfacial stability in solid-state batteries, yet (electro)chemical degradation of polymerized interfaces, especially at high voltages, remains a critical challenge. Herein, we find interphase engineering is crucial for the polymerization process and polymer stability and pioneer an in situ polymerization-fluorination (Poly-FR) strategy to create durable interfaces with excellent physical and (electro)chemical stabilities, achieved by designing a bifunctional initiator for both polymerization and on-surface lithium donor reactions. The integrated in situ fluorination converts LiCO impurities on LiNiCoMnO (NCM811) surfaces into LiF-rich interphases, effectively inhibiting the aggressive (de)lithiation intermediates and protecting the interface from underlying chemical degradation, thereby surpassing the stability limitations of polymerization alone.
View Article and Find Full Text PDFThianthrenium-Enabled Chromium-Catalyzed Deuterated Alkyl Addition to Aldehydes via a Photoactive Electron Donor-Acceptor Complex.
Org Lett
January 2025
Department of Chemistry and Materials Science, College of Science, Nanjing Forestry University, Nanjing 210037, China.
The Nozaki-Hiyama-Kishi reaction offers effective and reliable strategies for the preparation of alcohols via carbon-carbon bond formation. Typical methods usually require stoichiometric amounts of chromium salts, co-transition metals, and auxiliary reagents, which limits their practical application in industrial chemistry. To mitigate these limitations, substantial efforts have been made to develop chromium-catalytic approaches.
View Article and Find Full Text PDFUtility of large V-Y advancement of the latissimus dorsi myocutaneous flap in the reconstruction of large thoracic defects: a case series and literature review.
JPRAS Open
March 2025
Sir Charles Gairdner Hospital, Nedlands, Perth, Western Australia, 6009.
Background: Trunk reconstruction following sarcoma excision involves significant defects. Pedicled and free latissimus dorsi myocutaneous flap (LDMF) reconstruction is commonly employed for thoracic defects; however, skin paddle design is limited to 10-12 cm to achieve primary donor closure. Paucity of data exists regarding the utility of V-Y advancement of LDMF, previously described for moderately sized thoracic defects.
View Article and Find Full Text PDFIndications and outcomes of liver transplantation for liver tumors in the United States.
Surg Pract Sci
June 2024
Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
Background: While hepatocellular carcinoma (HCC) remains the leading cause of liver transplant (LT) for liver tumors, indications have broadened over the years. Data regarding patient characteristics and outcomes of LT for liver tumors are limited.
Methods: From Jan-2002 to March-2022, 14,406 LT recipients for various liver tumors were identified in United Network for Organ Sharing database.
The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis.
Front Oncol
January 2025
Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Introduction: CD7 chimeric antigen receptor T-cell (CAR-T cell) therapy is an emerging method for treating hematological malignancies, and is another breakthrough in CAR-T cell therapy.
Methods: This study summarizes the currently published clinical research results on CD7 CAR-T cells and evaluates the safety and effectiveness of CD7 CAR-T cell therapy.
Results: Among the 13 studies included in this study, a total of 200 patients received CD7 CAR-T cell therapy, including 88 patients who received autologous CAR-T cells, 112 patients who received donor derived CAR-T cells.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!